Massachusetts Financial Services CO Voyager Therapeutics, Inc. Transaction History

Massachusetts Financial Services CO

$299 Billion
Q4 2024

A detailed history of Massachusetts Financial Services CO transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Massachusetts Financial Services CO holds 186,000 shares of VYGR stock, worth $758,880. This represents 0.0% of its overall portfolio holdings.

Number of Shares

186,000

Previous 171,856 8.23%

Holding current value

$758,880

Previous $1.01 Million 4.88%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$5.27 - $8.07 $74,538 - $114,142	14,144 Added 8.23%	186,000 $1.05 Million
Q3 2024 Nov 12, 2024	BUY	$5.77 - $9.27 $163,481 - $262,646	28,333 Added 19.74%	171,856 $1.01 Million
Q2 2024 Aug 09, 2024	BUY	$7.42 - $10.54 $35,734 - $50,760	4,816 Added 3.47%	143,523 $1.14 Million
Q1 2024 May 14, 2024	BUY	$7.15 - $10.84 $198,634 - $301,146	27,781 Added 25.04%	138,707 $1.29 Million
Q4 2023 Feb 08, 2024	SELL	$6.28 - $8.81 $22,011 - $30,879	-3,505 Reduced 3.06%	110,926 $936,000
Q3 2023 Nov 08, 2023	BUY	$7.55 - $11.25 $863,954 - $1.29 Million	114,431 New	114,431 $886,000
Q2 2021 Aug 13, 2021	SELL	$3.94 - $5.44 $216,219 - $298,536	-54,878 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$4.61 - $9.04 $266,020 - $521,653	-57,705 Reduced 51.26%	54,878 $258,000
Q4 2020 Feb 12, 2021	SELL	$7.15 - $12.28 $8,072 - $13,864	-1,129 Reduced 0.99%	112,583 $805,000
Q3 2020 Nov 12, 2020	SELL	$10.01 - $13.75 $44,614 - $61,283	-4,457 Reduced 3.77%	113,712 $1.21 Million
Q2 2020 Aug 11, 2020	BUY	$8.05 - $14.21 $951,260 - $1.68 Million	118,169 New	118,169 $1.49 Million

Others Institutions Holding VYGR

# of Institutions

135

Shares Held

34.4M

Call Options Held

Put Options Held

60.4K

View Full List

About Voyager Therapeutics, Inc.

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $158M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

More about VYGR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.

Account

Massachusetts Financial Services CO Voyager Therapeutics, Inc. Transaction History